=Affimed N.V. (AFMD) announces collaboration with Genentech (RHHBY)

The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014.

• Founded in 2000
• Headquartered in Heidelberg, Germany.
• affimed.com
• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 80

Affimed Therapeutics announces collaboration with Genentech (RHHBY) to develop novel NK cell engager-based immunotherapeutics for multiple cancer targets; will receive $96M upfront and committed funding and is eligible for up to an additional $5.0B including milestone payments, and royalties on sales 

• Co entered into a strategic collaboration agreement with Genentech, a member of the Roche Group (RHHBY), to develop and commercialize novel NK cell engager-based immunotherapeutics to treat multiple cancers.
• Affimed will apply its proprietary Redirected Optimized Cell Killing (ROCK) platform, which enables the generation of both NK cell and T cell-engaging antibodies, to discover and advance innate immune cell engager-based immunotherapeutics of interest to Genentech. The collaboration includes candidate products generated from Affimed's ROCK platform and multiple undisclosed solid and hematologic tumor targets. Affimed and Genentech will collaborate on the discovery, early research and late-stage research phases. Genentech will be responsible for clinical development and commercialization worldwide.
• Affimed will receive $96 million in an initial upfront payment and other near-term committed funding. Affimed may be eligible to receive up to an additional $5.0 billion over time, including payments upon achievement of specified development, regulatory and commercial milestones, and royalties on sales.